JP2016509864A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509864A5
JP2016509864A5 JP2015562504A JP2015562504A JP2016509864A5 JP 2016509864 A5 JP2016509864 A5 JP 2016509864A5 JP 2015562504 A JP2015562504 A JP 2015562504A JP 2015562504 A JP2015562504 A JP 2015562504A JP 2016509864 A5 JP2016509864 A5 JP 2016509864A5
Authority
JP
Japan
Prior art keywords
segment
seq
virus
identity
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562504A
Other languages
English (en)
Japanese (ja)
Other versions
JP6525469B2 (ja
JP2016509864A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/059729 external-priority patent/WO2014141125A2/en
Publication of JP2016509864A publication Critical patent/JP2016509864A/ja
Publication of JP2016509864A5 publication Critical patent/JP2016509864A5/ja
Application granted granted Critical
Publication of JP6525469B2 publication Critical patent/JP6525469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562504A 2013-03-13 2014-03-13 インフルエンザb型ウイルス再集合 Active JP6525469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779888P 2013-03-13 2013-03-13
US61/779,888 2013-03-13
PCT/IB2014/059729 WO2014141125A2 (en) 2013-03-13 2014-03-13 Influenza virus reassortment

Publications (3)

Publication Number Publication Date
JP2016509864A JP2016509864A (ja) 2016-04-04
JP2016509864A5 true JP2016509864A5 (https=) 2017-04-20
JP6525469B2 JP6525469B2 (ja) 2019-06-05

Family

ID=50440715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562504A Active JP6525469B2 (ja) 2013-03-13 2014-03-13 インフルエンザb型ウイルス再集合

Country Status (13)

Country Link
US (2) US10232031B2 (https=)
EP (1) EP2968512A2 (https=)
JP (1) JP6525469B2 (https=)
KR (1) KR20150130344A (https=)
CN (2) CN105338999B (https=)
AU (2) AU2014229255B2 (https=)
BR (1) BR112015021880A2 (https=)
CA (1) CA2905612A1 (https=)
HK (1) HK1218511A1 (https=)
IL (1) IL240936B (https=)
MX (1) MX372963B (https=)
SG (1) SG11201507454XA (https=)
WO (1) WO2014141125A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
IN2014CN02114A (https=) 2011-09-20 2015-05-29 Sinai School Medicine
EA201591164A1 (ru) 2012-12-18 2015-11-30 Икан Скул Оф Медсин Эт Маунт Синай Вакцины против вируса гриппа и их применение
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
HK1254344A1 (zh) 2015-06-26 2019-07-19 Seqirus UK Limited 抗原匹配的流感疫苗
HUE051783T2 (hu) 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CN108018300B (zh) 2017-11-21 2020-08-28 浙江迪福润丝生物科技有限公司 区分免疫和感染动物h7亚型禽流感疫苗株及其制备方法和应用
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN114262694B (zh) * 2021-12-06 2023-11-03 军事科学院军事医学研究院军事兽医研究所 以B型流感病毒为载体的SARS-CoV-2疫苗候选株及其构建方法和应用
CN116063409A (zh) * 2022-09-09 2023-05-05 中山大学·深圳 一种乙型流感Mosaic重组蛋白、重组质粒及其构建方法和应用
CN118978590B (zh) * 2024-10-12 2025-01-21 北京溯本源和生物科技有限公司 一种利用重组流感病毒免疫小鼠制备杂交瘤单抗的方法及应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ATE384126T1 (de) 1998-06-12 2008-02-15 Sinai School Medicine Interferon induzierende genetisch veränderte attenuierte viren
IT1307930B1 (it) * 1999-01-26 2001-11-29 Sinco Ricerche Spa Articoli trasparenti in resina poliestere (mg32).
TR200200776T2 (tr) 1999-09-24 2002-06-21 Smithkline Beecham Biologicals S.A. Burun içi grip virüsü aşısı.
JP4698112B2 (ja) 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法
AU2002221624A1 (en) 2000-09-25 2002-04-02 Bayer Aktiengesellschaft Human e3 ubiquitin protein ligase-like enzyme
US7494659B2 (en) 2000-09-25 2009-02-24 Polymun Scientific Immunbiologische Forschung Gmbh Live attenuated influenza vaccine
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
JP2004536785A (ja) 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
AU2005230708B2 (en) 2004-04-05 2009-01-15 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
EP2995678A1 (en) * 2004-05-24 2016-03-16 MedImmune, LLC Multi plasmid system for the production of attenuated influenza b virus
ATE547511T1 (de) 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
EP2441471B1 (en) * 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
RU2008101367A (ru) 2005-06-21 2009-08-10 Медиммун, Ллк (Us) Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CA2627971A1 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
WO2007126810A2 (en) * 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
PT2016194E (pt) 2006-04-19 2015-07-20 Medimmune Llc Métodos e composições para expressar arn viral de polaridade negativa em células caninas
KR101151202B1 (ko) 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
WO2010006144A2 (en) * 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants
JP5686741B2 (ja) 2008-12-16 2015-03-18 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated インフルエンザワクチンの生成
EP2573184A1 (en) 2009-05-21 2013-03-27 Novartis AG Reverse genetics using non-endogenous POL I promoters
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
CN102741399A (zh) 2009-10-20 2012-10-17 诺华有限公司 用于病毒拯救的改良反向遗传方法
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method

Similar Documents

Publication Publication Date Title
JP2016509864A5 (https=)
JP2015119730A5 (https=)
JP2016521553A5 (https=)
JP2016501020A5 (https=)
Milián et al. Current and emerging cell culture manufacturing technologies for influenza vaccines
Cauldwell et al. Viral determinants of influenza A virus host range
Horimoto et al. Enhanced growth of seed viruses for H5N1 influenza vaccines
JP2019011344A5 (https=)
Zhou et al. Characterization of uncultivable bat influenza virus using a replicative synthetic virus
Petiot et al. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17
WO2008156681A2 (en) Adenoviral vectors for influenza virus production
JP2017189179A5 (https=)
CA2848117A1 (en) Recombinant influenza virus highly expressing ha protein and preparation method and use thereof
JP2018064493A (ja) Mdck細胞を用いたインフルエンザウイルスの増殖方法
Li et al. Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome
Van Wielink et al. Adaptation of a Madin–Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines
Minor et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK
Chen et al. Partial and full PCR-based reverse genetics strategy for influenza viruses
Mostafa et al. The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs
Johnson et al. Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs
US11883483B2 (en) Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
Shao et al. An efficient and rapid influenza gene cloning strategy for reverse genetics system
CN104195154A (zh) 新城疫病毒Mukteswar中等毒力疫苗株反向遗传操作系统及其应用
Zhou et al. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1
Koudstaal et al. Suitability of PER. C6® cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics